Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

John Carson

Vascular Surgery Scarborough, ME Medical Doctor

NPI 1871507228 CMS profile 265937

92 Campus Dr Ste D, Scarborough, ME 04074

Open in the dashboard

General payments

$26,341

177 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, John Carson of Scarborough, ME is reported in the CMS Open Payments database as having received $26,341 across 177 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,303 45
2024 General $2,580 26
2023 General $14,263 38
2022 General $402 12
2021 General $2,794 16
2020 General $124 7
2019 General $1,875 33

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Carson
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to John Carson were reported at $4,303. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year John Carson Vascular Surgery median Middle half National median
2019 $1,875 $796 $226–$2,363 $163
2020 $124 $348 $118–$1,110 $114
2021 $2,794 $471 $158–$1,421 $132
2022 $402 $725 $222–$2,183 $149
2023 $14,263 $836 $257–$2,440 $160
2024 $2,580 $909 $252–$2,619 $164
2025 $4,303 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $10,233 22 payments
  2. Cordis US Corp. $4,599 5 payments
  3. W. L. Gore & Associates, Inc. $2,365 27 payments
  4. Medtronic, Inc. $2,110 28 payments
  5. VB Spine LLC $1,774 10 payments
  6. Penumbra, Inc. $1,313 19 payments
  7. Becton, Dickinson and Company $552 5 payments
  8. Cook Medical LLC $519 7 payments
  9. Silk Road Medical, Inc. $432 5 payments
  10. Bard Peripheral Vascular, Inc. $401 19 payments
  11. Other $2,043 30 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,553 150 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $8,100 3 payments
  3. Travel and Lodging $5,138 21 payments
  4. Consulting Fee $4,550 3 payments
Products named General payments · program years 2019–2025
  1. Varithena Administration Pack $9,160 8 payments
  2. SABER $2,292 2 payments
  3. STRYKER $1,435 8 payments
  4. ENDURANT IIS $1,310 19 payments
  5. Lantern $1,046 3 payments
  6. GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis $986 8 payments
  7. GORE TAG Thoracic Branch Endoprosthesis $715 9 payments
  8. Indigo $642 10 payments
  9. ENROUTE Transcarotid Stent $375 4 payments
  10. ENROUTE Transcarotid Neuroprotection System $375 4 payments
  11. Other $6,779 98 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

15

Median for Vascular Surgery: 122

Drug cost

$64

Median for Vascular Surgery: $14,135

Branded share of claims

100%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clopidogrel Clopidogrel Bisulfate Brand 15 $64

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 91 billing codes

Paid by Medicare

$48,502

Medicare's payments for the services billed

Medicare patients

188

Average age 73

Services billed

409

76 women, 112 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 49%
Ischemic heart disease 47%
Chronic kidney disease 40%
Diabetes 37%
Atrial fibrillation 30%
COPD 30%
Heart failure 29%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

177 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record